Latest News

CStone Pharmaceuticals previously announced that the UK MHRA has granted a new indication for sugemalimab monotherapy in certain adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. This adds to approvals by the European Commission and UK MHRA across multiple non-small cell lung cancer settings, potentially broadening sugemalimab’s clinical footprint in key international markets. We will now examine how...

AppFolio recently outlined that revenue growth is outpacing customer additions as users adopt more paid services, supporting higher free-cash-flow margins and a broader mix of income streams, including services sold directly to residents on its platform. Management’s guidance for 2026, including revenue of about US$1.10 billion and a larger adjusted operating margin near 26.5%, highlights how operating leverage and deeper monetization per unit are reshaping the company’s profit...

Bayer FY 2025 earnings snapshot Bayer (XTRA:BAYN) has capped FY 2025 with a tough final quarter, posting Q4 revenue of €11.4 billion and a basic EPS loss of €3.80, alongside a net loss of €3.8 billion. Over recent periods, the company has seen quarterly revenue move between €9.7 billion and €13.7 billion, while EPS has swung from a profit of €1.32 in Q1 2025 to losses in each of the following quarters. This keeps the focus firmly on how quickly margins can stabilize. With forecasts in the...

What Savaria’s latest earnings signal for investors Savaria (TSX:SIS) just reported record 2025 results, including its highest quarterly EBITDA, full year revenue of CA$913.53 million, and net income of CA$68.77 million, closing out its two year Savaria One transformation program. Earnings per share from continuing operations reached CA$0.96 on a basic basis and CA$0.95 on a diluted basis, while both the Accessibility and Patient Care segments contributed to the stronger full year...

If you are wondering whether Atlantic Union Bankshares is offering fair value at its current share price, this article walks through what the numbers are really saying about the stock. The shares most recently closed at US$36.56, with returns of 2.9% year to date and 14.2% over 1 year, while the past 7 days and 30 days have seen declines of 7.5% and 9.8% respectively. Recent moves in regional bank stocks, including Atlantic Union Bankshares, have been shaped by ongoing headlines around...

CSL (ASX:CSL) is back in focus after two fresh developments: a larger on market share buy back now covering nearly four million shares, and a new Canadian pandemic influenza vaccine contract for CSL Seqirus. See our latest analysis for CSL. Despite the fresh buy back and the Canadian vaccine contract, CSL's share price has had a weak patch, with a 30 day share price return of 19.5% and a 1 year total shareholder return decline of 42.6%, pointing to fading momentum after several tougher...

If you are wondering whether Concentrix is a bargain or a value trap at around US$34.50 per share, looking closely at its valuation story is a good place to start. The stock has recently shown a 7.6% gain over the last 7 days, but that comes after weaker returns of a 7.5% decline over 30 days, a 16.3% decline year to date, a 20.4% decline over 1 year, and 72.8% and 73.6% declines over 3 and 5 years respectively. These moves have been happening alongside ongoing attention on Concentrix as a...

Context for Renesas Electronics after recent performance moves Renesas Electronics (TSE:6723) has drawn fresh attention after a mixed stretch of returns, with a small 1 day decline, a weaker past week, and positive performance over the month and past 3 months. For investors following the stock, this pattern, together with a 1 year total return in positive territory and multi year gains, raises questions about how current pricing lines up with its fundamentals and risk profile. See our latest...

In late February 2026, Mesoblast reported half-year results showing revenue of US$51.34 million, a very large increase from US$3.16 million a year earlier, alongside a narrower net loss of US$40.16 million and reduced loss per share. Soon after, the company issued fiscal 2026 guidance projecting full-year Ryoncil net revenue between US$110 million and US$120 million, giving investors a clearer view of the therapy’s commercial trajectory. With Mesoblast now guiding Ryoncil net revenue of...

If you are wondering whether Saia's current share price lines up with its underlying worth, you are not alone. This article is going to focus squarely on what you are paying versus what you might be getting. Saia's stock closed at US$396.62, with a 1.9% decline over the last 7 days, a 6.0% return over 30 days, 17.6% year to date, 3.7% over 1 year, 41.3% over 3 years, and 82.3% over 5 years. This gives you a wide range of time frames to think about risk and reward. Recent news coverage around...

What the latest earnings and M&A plans mean for Everus Construction Group stock Everus Construction Group (ECG) just paired a strong 2025 earnings update with 2026 revenue guidance of US$4.1b to US$4.2b, alongside plans to pursue acquisitions using its current balance sheet capacity. See our latest analysis for Everus Construction Group. The earnings update and new M&A push come after a sharp run in the shares, with a 1 month share price return of 20.5% and a year to date share price return...

In late February 2026, Ambarella, Inc. reported fourth-quarter sales of US$100.87 million and a net loss of US$16.44 million, alongside full-year sales of US$390.70 million and a reduced annual net loss of US$75.87 million compared with the prior year. Management also issued revenue guidance of US$97.00 million to US$103.00 million for the first quarter of fiscal 2027 and projected total revenue growth of 10% to 15% for fiscal 2027, underscoring ongoing demand for its Edge-AI system-on-chip...

Bullish (BLSH) has caught investor attention after a recent swing in performance, with the stock showing a mix of sharp short term gains and declines across the past week and past 3 months. See our latest analysis for Bullish. At a share price of $35.02, Bullish reflects a sharp 26.7% 1 month share price return but a weaker 10.8% year to date share price return, suggesting recent momentum has picked up after earlier weakness. If Bullish’s swings have you thinking about where else growth...

Lumine Group (TSXV:LMN) closed out FY 2025 with Q4 revenue of US$216.3 million and basic EPS of US$0.19, while trailing twelve month figures stood at US$765.7 million in revenue and EPS of US$0.46 as earnings moved into positive territory over the past year. The company reported quarterly revenue rising from US$187.1 million in Q4 2024 to US$216.3 million in Q4 2025, with basic EPS increasing from US$0.11 to US$0.19 over the same period, indicating firmer margins underpinning the latest...

If you are trying to figure out whether Archrock's current share price lines up with its underlying worth, you are in the right place. Archrock's share price recently closed at US$35.80, with returns of 1.0% over 7 days, 20.0% over 30 days, 34.4% year to date and 56.3% over 1 year, while the 3 year and 5 year returns are very large. Recent coverage has focused on Archrock's position in the energy infrastructure space and how investors might be thinking about its long term cash generation and...

If you are wondering whether ArriVent BioPharma's current share price lines up with its underlying worth, you are exactly the audience this valuation focused review is written for. The stock last closed at US$25.25, with reported returns of 8.7% over 7 days, 11.6% over 30 days, 21.4% year to date, and 15.8% over the past year. Recent price moves sit against a backdrop of ArriVent BioPharma working to bring its pipeline to market and building out its position in the pharmaceuticals and...

If you are wondering whether Lindblad Expeditions Holdings at around US$18.21 is still offering value after a strong run, you are not alone. The stock has seen a 10% decline over the last 7 days, after a 4.4% gain over 30 days, and it sits on year to date and 1 year returns of 26.1% and 72.8% respectively, with a 3 year return of 108.8% and a 5 year return of a 9.9% decline. This mix of recent pullback and longer term gains often lines up with changing expectations around growth, risk, or...

Military conflict in the Middle East has led to the closure of the Strait of Hormuz, disrupting a key global energy and shipping route. This chokepoint closure is creating volatility across mining and metals companies, including Southern Copper (NYSE:SCCO), as fuel supply and transport risks rise. Investors are watching how higher energy costs and logistical challenges could affect operating expenses and margins for producers such as Southern Copper. Southern Copper, listed as NYSE:SCCO, is...

WD-40 (WDFC) recently reported a quarter with flat revenue along with softer earnings per share and EBITDA versus analyst expectations, yet the stock has climbed 16% since the release, catching investors’ attention. See our latest analysis for WD-40. That post earnings jump and the 23.67% 90 day share price return stand in contrast to a 0.81% decline in 1 year total shareholder return, so recent momentum has picked up after a weaker stretch. If WD-40’s move has you curious about where else...

Ituran Location and Control (NasdaqGS:ITRN) is in focus after the board approved a US$1.50 per share cash dividend, totaling about US$30 million, with a reduced 20% withholding tax rate. See our latest analysis for Ituran Location and Control. The dividend news arrives after a sharp move in the share price, with a 1-day share price return of 9.98% taking Ituran Location and Control to US$50.47. This builds on a 90-day share price return of 22.86% and a 1-year total shareholder return of...

If you are asking yourself whether Limbach Holdings at around US$81.51 is still good value or starting to look expensive, this review is for you. The stock has moved around recently, with a 7 day return of a 16.8% decline, a 30 day return of a 9.1% decline, a 3.1% gain year to date, and an 11.6% gain over the past year. The 3 year return is very large and the 5 year return is also very large. Recent coverage has focused on Limbach as a specialist player in capital goods and building systems,...

ARC Resources (TSX:ARX) has just closed a CAD 950 million senior unsecured notes offering, reallocating its debt between new Series 5 and Series 6 notes while planning to redeem earlier notes and repay its term loan. See our latest analysis for ARC Resources. The refinancing news comes as ARC Resources' share price sits at CA$25.91, with a 1-day share price return of 1.17% and a 7-day share price return of 3.89%. Its 1-year total shareholder return of 6.83% contrasts with a softer 90-day...

GFL Environmental (TSX:GFL) has put a fresh spotlight on its stock after the Board approved a normal course issuer bid to repurchase up to 10% of its subordinate voting shares. See our latest analysis for GFL Environmental. The buyback plan lands at a time when GFL Environmental’s share price has been firming in the short term, with a 1 month share price return of 5.24% and a year to date share price return of 4.06%. Over a longer period, the 1 year total shareholder return shows a 7.60%...

In recent days, Amkor Technology has faced sector-wide pressure as geopolitical tensions raised concerns about a potential global liquefied natural gas cost shock for semiconductor manufacturers, even as it continues building a US$7.00 billion advanced-packaging campus in Arizona slated for completion in the late 2020s. This mix of higher energy cost fears and large-scale investment in advanced packaging, supported by potential US government incentives, is sharpening investor focus on...